Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 57Carcinoma, Ovarian Epithelial 28Fallopian Tube Neoplasms 20Uterine Cervical Neoplasms 17Endometrial Neoplasms 17Breast Neoplasms 13Stomach Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 9Prostatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7Esophageal Neoplasms 7Carcinoma, Renal Cell 7Peritoneal Neoplasms 6Melanoma 6Uterine Neoplasms 4Urinary Bladder Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma 4Pancreatic Neoplasms 4Neoplasms 4Head and Neck Neoplasms 4Esthesioneuroblastoma, Olfactory 4Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Kidney Neoplasms 3Brenner Tumor 3

Interventions

Bevacizumab 21-dodecylpyridoxal 2tremelimumab 1durvalumab 1Paclitaxel 1Injections 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-resistant Recurrent Ovarian Cancer × Docetaxel × Gynecologic × Clear all
NCT05325229 2022-10-13

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
94 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡